ClinicalTrials.gov
public full text
Public Domain
Dosing Flexibility Study in Patients With Rheumatoid Arthritis
During the run-in period, CZP will be administered at 400 mg (2 injections) at Wks 0, 2, and 4 and 200 mg with placebo (1 injection placebo, 1 injection CZP) at Wks 6, 8, 10, 12, 14 and 16. At Wk 18 patients will be grouped as responders or non-responders based on results of the ACR20 at Week 16.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA)#888220
- A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients#1010623
- Sacral Nerve Stimulation for Mild-to-Moderate or Refractory Rheumatoid Arthritis#1060508
- A Clinical Study to Investigate the Effect on Pain Relief of a Single Dose of JNJ-39439335 in Patients With Chronic Osteoarthritis Pain of the Knee#1094622
- An Relative Bioavailability Study of BH006 for Injection in Healthy Subjects#992830
Record · ID 1008199
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive